Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $23.50.

Several research firms recently issued reports on STOK. Credit Suisse Group reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 8th. TD Cowen cut shares of Stoke Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 25th. Needham & Company LLC reissued a “buy” rating and set a $25.00 target price on shares of Stoke Therapeutics in a report on Monday, August 7th. Cantor Fitzgerald dropped their target price on shares of Stoke Therapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 8th.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 15,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $10.60, for a total transaction of $159,000.00. Following the completion of the transaction, the insider now owns 25,895 shares in the company, valued at $274,487. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, General Counsel Jonathan Allan sold 1,948 shares of the stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $13.48, for a total value of $26,259.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 15,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $10.60, for a total transaction of $159,000.00. Following the transaction, the insider now owns 25,895 shares of the company’s stock, valued at approximately $274,487. The disclosure for this sale can be found here. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in the business. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 13.4% during the 1st quarter. RTW Investments LP now owns 4,390,558 shares of the company’s stock valued at $36,573,000 after purchasing an additional 519,577 shares in the last quarter. Cowen AND Company LLC boosted its position in shares of Stoke Therapeutics by 13.5% during the 2nd quarter. Cowen AND Company LLC now owns 3,721,659 shares of the company’s stock valued at $39,561,000 after purchasing an additional 442,517 shares in the last quarter. BlackRock Inc. boosted its position in shares of Stoke Therapeutics by 24.3% during the 2nd quarter. BlackRock Inc. now owns 2,293,670 shares of the company’s stock valued at $24,382,000 after purchasing an additional 448,175 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Stoke Therapeutics by 90.8% during the first quarter. Baker BROS. Advisors LP now owns 2,115,416 shares of the company’s stock valued at $17,621,000 after buying an additional 1,006,503 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Stoke Therapeutics by 2.7% during the third quarter. Vanguard Group Inc. now owns 2,047,904 shares of the company’s stock valued at $26,295,000 after buying an additional 52,871 shares in the last quarter.

Stoke Therapeutics Stock Down 4.8 %

Shares of STOK opened at $4.97 on Thursday. The firm has a market cap of $219.96 million, a price-to-earnings ratio of -1.96 and a beta of 0.35. The business’s 50 day moving average is $7.05 and its two-hundred day moving average is $9.03. Stoke Therapeutics has a 52-week low of $4.93 and a 52-week high of $17.10.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.06). The company had revenue of ($2.48) million during the quarter, compared to analyst estimates of $4.00 million. Stoke Therapeutics had a negative net margin of 679.83% and a negative return on equity of 52.94%. On average, equities analysts expect that Stoke Therapeutics will post -2.58 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.